Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors ; volume:22 ; number:1 ; day:8 ; month:2 ; year:2024 ; pages:1-28 ; date:12.2024
Cell communication and signaling ; 22, Heft 1 (8.2.2024), 1-28, 12.2024
- Urheber
-
Pakjoo, Mahdi
Ahmadi, Seyed Esmaeil
Zahedi, Mohammad
Jaafari, Niloofar
Khademi, Reyhane
Amini, Ali
Safa, Majid
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12964-023-01433-5
- URN
-
urn:nbn:de:101:1-2404170740534.075647736123
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pakjoo, Mahdi
- Ahmadi, Seyed Esmaeil
- Zahedi, Mohammad
- Jaafari, Niloofar
- Khademi, Reyhane
- Amini, Ali
- Safa, Majid
- SpringerLink (Online service)
Ähnliche Objekte (12)
Proteasome inhibitors against amelanotic melanoma
Gastrointestinal toxicities of proteasome inhibitor therapy
Characterisation and optimisation of 20S proteasome inhibitors
Characterisation and optimisation of 20S proteasome inhibitors
Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
BU-32: a novel proteasome inhibitor for breast cancer
Positioning of proteasome inhibitors in therapy of solid malignancies
Patented small molecule inhibitors in the ubiquitin proteasome system
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs
Gastric cancer cell types display distinct proteasome/immunoproteasome patterns associated with migration and resistance to proteasome inhibitors
Proteasome inhibitors against amelanotic melanoma
Gastrointestinal toxicities of proteasome inhibitor therapy
Characterisation and optimisation of 20S proteasome inhibitors
Characterisation and optimisation of 20S proteasome inhibitors
Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
BU-32: a novel proteasome inhibitor for breast cancer
Positioning of proteasome inhibitors in therapy of solid malignancies
Patented small molecule inhibitors in the ubiquitin proteasome system
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs
Gastric cancer cell types display distinct proteasome/immunoproteasome patterns associated with migration and resistance to proteasome inhibitors
Proteasome inhibitors against amelanotic melanoma
Gastrointestinal toxicities of proteasome inhibitor therapy
Characterisation and optimisation of 20S proteasome inhibitors
Characterisation and optimisation of 20S proteasome inhibitors
Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
BU-32: a novel proteasome inhibitor for breast cancer
Positioning of proteasome inhibitors in therapy of solid malignancies
Patented small molecule inhibitors in the ubiquitin proteasome system
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs